Disclosed are compounds for SH2 domain binding inhibition. For example,
disclosed is a compound of formula (I)
##STR1##
wherein R1 is a lipophile; R2, in combination with
the phenyl ring, forms a phenylphosphate mimic group or a protected phenylphosphate
mimic group; R3 is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl,
aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3
may be optionally substituted with a substituent selected from the group
consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto;
R6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof.
Also disclosed are a pharmaceutical composition, a method for inhibiting an SH2
domain from binding with a phosphoprotein and a method of treating breast cancer.